IN THE CLAIMS

The listing of the claims which follows replaces any and all prior versions and/or listings of the claims in the application.

1. (previously presented) A compound according to claim 20, which is a compound of Formula II, or a pharmaceutically acceptable salt thereof:



(II),

wherein:

X^1 and X^2 are each independently:

(1) -H,
(2) -C_{1-6} alkyl,
(3) -O-C_{1-6} alkyl,
(4) -C_{1-6} haloalkyl,
(5) -O-C_{1-6} haloalkyl,
(6) halogen,
(7) -CN,
(8) -$N(R^a)R^b$,
(9) -$C(=O)N(R^a)R^b$,
(10) -SR^a,
(11) -$S(O)R^a$,
(12) -SO_2R^a,
(13) -$N(R^a)SO_2R^b$,
(14) -$N(R^a)SO_2N(R^a)R^b$,
(15) -$N(R^a)C(=O)R^b$,
(16) -$N(R^a)C(=O)$-$C(=O)N(R^a)R^b$,
(17) -HetA,
(18) -C(=O)-HetA, or
(19) HetB;

wherein each HetA is independently a C_{4-5} azacycloalkyl or a C_{3-4} diazacycloalkyl, either of which is optionally substituted with 1 or 2 substituents each of which is independently oxo or C_{1-6} alkyl; and with the proviso that when

HetA is attached to the rest of the compound via the -C(=O)- moiety, the HetA is attached to the -C(=O)- via a ring N atom; and

each HetB is independently a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein the heteroaromatic ring is optionally substituted with from 1 to 4 substituents each of which is independently halogen, -C_{1-6} alkyl, -C_{1-6} haloalkyl, -O-C_{1-6} alkyl, -O-C_{1-6} haloalkyl, or hydroxy;

R^4 is:

(1) -CO_2R^a,

(2) -C(=O)N(R^a)R^b,

(3) -C(=O)-N(R^a)-$(CH_2)_{2-3}$-OR^b,

(4) -N(R^a)C(=O)R^b,

(5) -N(R^a)SO_2R^b,

(6) -HetK,

(7) -C(=O)-HetK,

(8) -C(=O)N(R^a)-$(CH_2)_{0-1}$-(C_{3-6} cycloalkyl), wherein the cycloalkyl is optionally substituted with from 1 to 4 substituents each of which is independently halogen, -C_{1-6} alkyl, -CF_3, -O-C_{1-6} alkyl, or -OCF_3, or

(9) -C(=O)N(R^a)-CH_2-phenyl, wherein the phenyl is optionally substituted with from 1 to 4 substituents each of which is independently -C_{1-6} alkyl, -O-C_{1-6} alkyl, -CF_3, -OCF_3, or halogen;

wherein HetK is a 5- or 6-membered saturated heterocyclic ring containing a total of from 1 to 4 heteroatoms independently selected from 1 to 4 N atoms, from 0 to 2 O atoms, and from 0 to 2 S atoms, wherein the heterocyclic ring is optionally substituted with from 1 to 4 substituents each of which is independently -C_{1-6} alkyl or oxo; and with the proviso that when HetK is attached to the rest of the compound via the -C(=O)- moiety, the HetK is attached to the -C(=O)- via a ring N atom;

R^5 is:

(1) -H,

(2) -C_{1-6} alkyl,

(3) -C_{3-6} cycloalkyl,

(4) -$(CH_2)_{1-2}$-C_{3-6} cycloalkyl, or

(5) -CH_2-phenyl;

each R^a is independently H or C_{1-6} alkyl; and

each R^b is independently H or C_{1-6} alkyl.

2. (previously presented) The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein:

X^1 and X^2 are each independently:

(1) -H,
(2) -C_{1-4} alkyl,
(3) -C_{1-4} haloalkyl,
(4) -O-C_{1-4} alkyl,
(5) halogen,
(6) -CN,
(7) -C(=O)NH_2,
(8) -C(=O)NH(-C_{1-4} alkyl),
(9) -C(=O)N(-C_{1-4} alkyl)$_2$, or
(10) -SO_2-C_{1-4} alkyl;

R^4 is:

(1) -CO_2H,
(2) -C(=O)-O-C_{1-4} alkyl,
(3) -C(=O)NH_2,
(4) -C(=O)NH-C_{1-4} alkyl,
(5) -C(=O)N(C_{1-4} alkyl)$_2$,
(6) -C(=O)-NH-(CH_2)$_{2-3}$-O-C_{1-4} alkyl,
(7) -C(=O)-N(C_{1-4} alkyl)-(CH_2)$_{2-3}$-O-C_{1-4} alkyl,
(8) -NHC(=O)-C_{1-4} alkyl,
(9) -N(C_{1-4} alkyl)C(=O)-C_{1-4} alkyl,
(10) -NHSO_2-C_{1-4} alkyl,
(11) -N(C_{1-4} alkyl)SO_2-C_{1-4} alkyl,
(12) -C(=O)-HetK, wherein HetK is:



wherein the asterisk * denotes the point of attachment to the rest of the compound,

(13) -C(=O)NH-$(CH_2)_{0-1}$-(C_{3-6} cycloalkyl),

(14) -C(=O)N(C_{1-4} alkyl)-$(CH_2)_{0-1}$-(C_{3-6} cycloalkyl),

(15) -C(=O)NH-CH_2-phenyl, or

(16) -C(=O)N(C_{1-4} alkyl)-CH_2-phenyl; and

R^5 is:

(1) -H,
(2) -C_{1-4} alkyl,
(3) -C_{3-6} cycloalkyl,
(4) -CH_2-C_{3-6} cycloalkyl, or
(5) -CH_2-phenyl.

3. (previously presented) The compound according to claim 1, or a pharmaceutically acceptable salt thereof, which is a compound of Formula III:



(III)

wherein:

X^1 is:

(1) -H,
(2) bromo,
(3) chloro,
(4) fluoro, or
(5) methoxy;

X^2 is:

(1) -H,

(2) bromo,
(3) chloro,
(4) fluoro,
(5) methoxy,
(6) -C_{1-4} alkyl,
(7) -CF_3,
(8) -OCF_3,
(9) -CN, or
(10) -$SO_2(C_{1-4}$ alkyl);

R^4 is:

(1) -CO_2H,
(2) -C(=O)-O-C_{1-4} alkyl,
(3) -$C(=O)NH_2$,
(4) -C(=O)NH-C_{1-4} alkyl,
(5) -$C(=O)N(C_{1-4}$ alkyl)$_2$,
(6) -C(=O)-NH-$(CH_2)_{2-3}$-O-C_{1-4} alkyl,
(7) -C(=O)-N(C_{1-4} alkyl)-$(CH_2)_{2-3}$-O-C_{1-4} alkyl,
(8) -NHC(=O)-C_{1-4} alkyl,
(9) -N(C_{1-4} alkyl)C(=O)-C_{1-4} alkyl,
(10) -$NHSO_2$-C_{1-4} alkyl,
(11) -N(C_{1-4} alkyl)SO_2-C_{1-4} alkyl,
(12) -C(=O)-HetK, wherein HetK is:



wherein the asterisk * denotes the point of attachment to the rest of the compound,
(13) -C(=O)NH-$(CH_2)_{0-1}$-(C_{3-6} cycloalkyl),
(14) -C(=O)N(C_{1-4} alkyl)-$(CH_2)_{0-1}$-(C_{3-6} cycloalkyl),
(15) -C(=O)NH-CH_2-phenyl, or
(16) -C(=O)N(C_{1-4} alkyl)-CH_2-phenyl; and

R^5 is:

(1) -H,
(2) -C_{1-4} alkyl,
(3) cyclopropyl,

(4) cyclobutyl,
(5) -CH_2-cyclopropyl,
(6) -CH_2-cyclobutyl, or
(7) -CH_2-phenyl.

4. (canceled)

5. (canceled)

6. (canceled)

7. (canceled)

8. (canceled)

9. (previously presented) A pharmaceutical composition comprising an effective amount of a compound according to claim 20, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

10. (canceled)

11. (currently amended) A method for ~~preventing or~~ treating infection by HIV or for ~~preventing,~~ treating or delaying the onset of AIDS in a subject in need thereof which comprises administering to the subject an effective amount of the compound according to claim 20, or a pharmaceutically acceptable salt thereof.

12. (canceled)

13. (canceled)

14. (canceled)

15. (canceled)

16. (original) A process for preparing a compound of Formula IV:



(IV),

which comprises:

(B) contacting a compound of Formula V:



(V)

with a Grignard salt of an amine of Formula VI:

$$HN(R^V)R^W \quad (VI)$$

to obtain Compound IV; wherein:

bond " $\overset{a}{\text{----}}$ " in the ring is a single bond or a double bond;

R^1 is -C_{1-6} alkyl substituted with R^J, wherein R^J is:

(A) aryl or aryl fused to a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein the aryl or fused aryl is:

(a) optionally substituted with from 1 to 5 substituents each of which is independently:

(1) -C_{1-6} alkyl,

(2) -C_{1-6} alkyl substituted with -O-C_{1-6} alkyl, -O-C_{1-6} haloalkyl, -NO_2, -$N(R^a)R^b$, or -$S(O)_nR^a$,

(3) -C_{1-6} haloalkyl,

(4) -O-C_{1-6} alkyl,

(5) halogen,

(6) $C(=O)N(R^a)R^b$, or

(7) -SO_2R^a, and

(b) optionally substituted with 1 or 2 substituents each of which is independently:

(1) phenyl,

(2) benzyl, or

(3) -HetB;

wherein each HetB is a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein the heteroaromatic ring is optionally substituted with from 1 to 4 substituents each of which is independently halogen, -C_{1-6} alkyl, -C_{1-6} haloalkyl, -O-C_{1-6} alkyl, or -O-C_{1-6} haloalkyl; or

(B) a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; wherein the heteroaromatic ring is

(i) optionally substituted with from 1 to 4 substituents each of which is independently halogen, -C_{1-6} alkyl, -C_{1-6} haloalkyl, -O-C_{1-6} alkyl, or -O-C_{1-6} haloalkyl, and

(ii) optionally substituted with 1 or 2 substituents each of which is independently aryl or -C_{1-6} alkyl substituted with aryl;

R^2 and R^3 are each independently -H or -C_{1-6} alkyl;

R^5 is:

(1) -C_{1-6} alkyl,

(2) -C_{3-8} cycloalkyl optionally substituted with from 1 to 4 substituents each of which is independently -C_{1-6} alkyl or -O-C_{1-6} alkyl,

(3) -C_{1-6} alkyl substituted with C_{3-8} cycloalkyl, wherein the cycloalkyl is optionally substituted with from 1 to 4 substituents each of which is independently -C_{1-6} alkyl or -O-C_{1-6} alkyl,

(4) -C_{1-6} alkyl substituted with aryl, wherein the aryl is optionally substituted with from 1 to 5 substituents each of which is independently -C_{1-6} alkyl, -C_{1-6} alkylene-O-C_{1-6} alkyl, or halogen, or

(5) -C_{1-6} alkyl substituted with a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein the heteroaromatic ring is optionally substituted with from 1 to 4 substituents each of which is independently -C_{1-6} alkyl;

R^T is -C_{1-6} alkyl;

R^V and R^W are each independently -C_{1-6} alkyl or R^V and R^W together with the N atom to which they are both attached form a 4- to 6-membered saturated heterocyclic ring optionally containing a heteroatom in addition to the nitrogen attached to R^V and R^W selected from N, O, and S, where the S is optionally oxidized to S(O) or $S(O)_2$, and wherein the saturated heterocyclic ring is optionally substituted with 1 or 2 substituents each of which is independently a C_{1-6} alkyl group;

each aryl is independently phenyl, naphthyl, or indenyl;

each R^a is independently H or C_{1-6} alkyl; and

each R^b is independently H or C_{1-6} alkyl.

17. (original) The process according to claim 16, wherein the process further comprises:

(A) treating a compound of Formula IX:



(IX)

with (i) a tertiary amine base in the presence of a lithium salt or (ii) an alkoxide base, to obtain a compound of Formula V; wherein one of bonds "$\overset{c}{=\!=\!=}$" and "$\overset{d}{=\!=\!=}$" is a single bond and the other is a double bond; and R^{T*} is C_{1-6} alkyl.

18. (original) A process for preparing a compound of Formula IV:



(IV),

which comprises treating a compound of Formula X:



(X)

with (i) a tertiary amine base in the presence of a lithium salt or (ii) an alkoxide base, to obtain a compound of Formula IV, wherein:

bond " $\overset{a}{=\!=\!=}$ " in the ring is a single bond or a double bond;

R^1 is -C_{1-6} alkyl substituted with R^J, wherein R^J is:

(A) aryl or aryl fused to a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein the aryl or fused aryl is:

(a) optionally substituted with from 1 to 5 substituents each of which is independently:

(1) -C_{1-6} alkyl,

(2) -C_{1-6} alkyl substituted with -O-C_{1-6} alkyl, -O-C_{1-6} haloalkyl, -NO_2, -$N(R^a)R^b$, or -$S(O)_nR^a$,

(3) -C_{1-6} haloalkyl,

(4) -O-C_{1-6} alkyl,

(5) halogen,

(6) $C(=O)N(R^a)R^b$, or

(7) -SO_2R^a, and

(b) optionally substituted with 1 or 2 substituents each of which is independently:

(1) phenyl,

(2) benzyl, or

(3) -HetB;

wherein each HetB is a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein the heteroaromatic ring is optionally substituted with from 1 to 4 substituents each of which is independently halogen, -C_{1-6} alkyl, -C_{1-6} haloalkyl, -O-C_{1-6} alkyl, or -O-C_{1-6} haloalkyl; or

(B) a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; wherein the heteroaromatic ring is

(i) optionally substituted with from 1 to 4 substituents each of which is independently halogen, -C_{1-6} alkyl, -C_{1-6} haloalkyl, -O-C_{1-6} alkyl, or -O-C_{1-6} haloalkyl, and

(ii) optionally substituted with 1 or 2 substituents each of which is independently aryl or -C_{1-6} alkyl substituted with aryl;

R^2 and R^3 are each independently -H or -C_{1-6} alkyl;

R^5 is:

(1) -C_{1-6} alkyl,

(2) -C_{3-8} cycloalkyl optionally substituted with from 1 to 4 substituents each of which is independently -C_{1-6} alkyl or -O-C_{1-6} alkyl,

(3) -C_{1-6} alkyl substituted with C_{3-8} cycloalkyl, wherein the cycloalkyl is optionally substituted with from 1 to 4 substituents each of which is independently -C_{1-6} alkyl or -O-C_{1-6} alkyl,

(4) -C_{1-6} alkyl substituted with aryl, wherein the aryl is optionally substituted with from 1 to 5 substituents each of which is independently -C_{1-6} alkyl, -C_{1-6} alkylene-O-C_{1-6} alkyl, or halogen, or

(5) -C_{1-6} alkyl substituted with a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein the heteroaromatic ring is optionally substituted with from 1 to 4 substituents each of which is independently -C_{1-6} alkyl;

R^V and R^W are each independently -C_{1-6} alkyl or R^V and R^W together with the N atom to which they are both attached form a 4- to 6-membered saturated heterocyclic ring optionally containing a heteroatom in addition to the nitrogen attached to R^V and R^W selected from N, O, and S, where the S is optionally oxidized to S(O) or $S(O)_2$, and wherein the saturated heterocyclic ring is optionally substituted with 1 or 2 substituents each of which is independently a C_{1-6} alkyl group;

each aryl is independently phenyl, naphthyl, or indenyl;

each R^a is independently H or C_{1-6} alkyl;

each R^b is independently H or C_{1-6} alkyl;

one of bonds "$\overset{c}{=\!=\!=}$" and "$\overset{d}{=\!=\!=}$" is a single bond and the other is a double bond; and

R^{T*} is C_{1-6} alkyl.

19. (original) A process for preparing a compound of Formula VII:



(VII)

which comprises reacting an alkylating agent of formula R^5-Z with a compound of Formula VIII:



(VIII)

in a polar aprotic solvent and in the presence of a base selected from a magnesium base and a calcium base; wherein:

bond " $\overset{a}{=\!=\!=}$ " in the ring is a single bond or a double bond;

W is -H or -C_{1-6} alkyl;

Z is halogen or -SO_3-Q wherein Q is (i) C_{1-6} alkyl or (ii) phenyl optionally substituted with 1 or 2 substituents each of which is independently a C_{1-6} alkyl;

R^S is -O-C_{1-6} alkyl or N(R^V)R^W wherein R^V and R^W are each independently -C_{1-6} alkyl or R^V and R^W together with the N atom to which they are both attached form a 4- to 6-membered saturated heterocyclic ring optionally containing a heteroatom in addition to the nitrogen attached to R^V and R^W selected from N, O, and S, where the S is optionally oxidized to S(O) or

$S(O)_2$, and wherein the saturated heterocyclic ring is optionally substituted with 1 or 2 substituents each of which is independently a C_{1-6} alkyl group;

R^1 is -C_{1-6} alkyl substituted with R^J, wherein R^J is:

(A) aryl or aryl fused to a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein the aryl or fused aryl is:

(a) optionally substituted with from 1 to 5 substituents each of which is independently:

(1) -C_{1-6} alkyl optionally substituted with -OH, -O-C_{1-6} alkyl, -O-C_{1-6} haloalkyl, -CN, -NO_2, -$N(R^a)R^b$, -$C(=O)N(R^a)R^b$, -$C(=O)R^a$, -CO_2R^a, -$S(O)_nR^a$, -$SO_2N(R^a)R^b$, -$N(R^a)C(=O)R^b$, -$N(R^a)CO_2R^b$, -$N(R^a)SO_2R^b$, -$N(R^a)SO_2N(R^a)R^b$, -$OC(=O)N(R^a)R^b$, or -$N(R^a)C(=O)N(R^a)R^b$,

(2) -O-C_{1-6} alkyl,

(3) -C_{1-6} haloalkyl,

(4) -O-C_{1-6} haloalkyl,

(5) -OH,

(6) halogen,

(7) -CN,

(8) -NO_2,

(9) -$N(R^a)R^b$,

(10) -$C(=O)N(R^a)R^b$,

(11) -$C(=O)R^a$,

(12) -CO_2R^a,

(13) -SR^a,

(14) -$S(=O)R^a$,

(15) -SO_2R^a,

(16) -$SO_2N(R^a)R^b$,

(17) -$N(R^a)SO_2R^b$,

(18) -$N(R^a)SO_2N(R^a)R^b$,

(19) -$N(R^a)C(=O)R^b$,

(20) -$N(R^a)C(=O)$-$C(=O)N(R^a)R^b$, or

(21) -$N(R^a)CO_2R^b$, and

(b) optionally substituted with 1 or 2 substituents each of which is independently:

(1) phenyl,

(2) benzyl,

(3) -HetA,

(4) -C(=O)-HetA, or

(5) -HetB;

wherein each HetA is independently a C_{4-7} azacycloalkyl or a C_{3-6} diazacycloalkyl, either of which is optionally substituted with from 1 to 4 substituents each of which is independently oxo or C_{1-6} alkyl; and

wherein each HetB is a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein the heteroaromatic ring is optionally substituted with from 1 to 4 substituents each of which is independently halogen, -C_{1-6} alkyl, -C_{1-6} haloalkyl, -O-C_{1-6} alkyl, -O-C_{1-6} haloalkyl, or hydroxy; or

(B) a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; wherein the heteroaromatic ring is

(i) optionally substituted with from 1 to 4 substituents each of which is independently halogen, -C_{1-6} alkyl, -C_{1-6} haloalkyl, -O-C_{1-6} alkyl, -O-C_{1-6} haloalkyl, or hydroxy, and

(ii) optionally substituted with 1 or 2 substituents each of which is independently aryl or -C_{1-6} alkyl substituted with aryl;

R^2 and R^3 are each independently -H or -C_{1-6} alkyl;

R^5 is:

(1) -C_{1-6} alkyl,

(2) -C_{3-8} cycloalkyl optionally substituted with from 1 to 4 substituents each of which is independently -C_{1-6} alkyl or -O-C_{1-6} alkyl,

(3) -C_{1-6} alkyl substituted with C_{3-8} cycloalkyl, wherein the cycloalkyl is optionally substituted with from 1 to 4 substituents each of which is independently -C_{1-6} alkyl or -O-C_{1-6} alkyl,

(4) -C_{1-6} alkyl substituted with aryl, wherein the aryl is optionally substituted with from 1 to 5 substituents each of which is independently -C_{1-6} alkyl, -C_{1-6} alkylene-O-C_{1-6} alkyl, or halogen, or

(5) -C_{1-6} alkyl substituted with a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein the heteroaromatic ring is optionally substituted with from 1 to 4 substituents each of which is independently -C_{1-6} alkyl;

each aryl is independently phenyl, naphthyl, or indenyl;

each R^a is independently H or C_{1-6} alkyl;

each R^b is independently H or C_{1-6} alkyl; and

each n is independently an integer equal to zero, 1, or 2.

20. (previously presented) A compound of Formula I, or a pharmaceutically acceptable salt thereof:



(I)

wherein:

bond " $\overset{a}{=\!=\!=}$ " in the ring is a single bond or a double bond;

R^1 is -C_{1-6} alkyl substituted with R^J, wherein R^J is:

(A) (i) aryl or (ii) aryl fused to a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein the aryl or fused aryl is:

(a) optionally substituted with from 1 to 5 substituents each of which is independently:

(1) -C_{1-6} alkyl optionally substituted with -OH, -O-C_{1-6} alkyl, -O-C_{1-6} haloalkyl, -CN, -NO_2, -$N(R^a)R^b$, -$C(=O)N(R^a)R^b$, -$C(=O)R^a$, -CO_2R^a, -$S(O)_nR^a$, -$SO_2N(R^a)R^b$, -$N(R^a)C(=O)R^b$,

$-N(R^a)CO_2R^b$, $-N(R^a)SO_2R^b$, $-N(R^a)SO_2N(R^a)R^b$, $-OC(=O)N(R^a)R^b$, or $-N(R^a)C(=O)N(R^a)R^b$,

(2) $-O-C_{1-6}$ alkyl,

(3) $-C_{1-6}$ haloalkyl,

(4) $-O-C_{1-6}$ haloalkyl,

(5) -OH,

(6) halogen,

(7) -CN,

(8) $-NO_2$,

(9) $-N(R^a)R^b$,

(10) $-C(=O)N(R^a)R^b$,

(11) $-C(=O)R^a$,

(12) $-CO_2R^a$,

(13) $-SR^a$,

(14) $-S(=O)R^a$,

(15) $-SO_2R^a$,

(16) $-SO_2N(R^a)R^b$,

(17) $-N(R^a)SO_2R^b$,

(18) $-N(R^a)SO_2N(R^a)R^b$,

(19) $-N(R^a)C(=O)R^b$,

(20) $-N(R^a)C(=O)-C(=O)N(R^a)R^b$, or

(21) $-N(R^a)CO_2R^b$, and

(b) optionally substituted with 1 or 2 substituents each of which is independently:

(1) phenyl,

(2) benzyl,

(3) -HetA,

(4) -C(=O)-HetA, or

(5) -HetB;

wherein each HetA is independently a C_{4-7} azacycloalkyl or a C_{3-6} diazacycloalkyl, either of which is optionally substituted with from 1 to 4 substituents each of which is independently oxo or C_{1-6} alkyl; and

wherein each HetB is independently a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein the

heteroaromatic ring is optionally substituted with from 1 to 4 substituents each of which is independently halogen, C_{1-6} alkyl, C_{1-6} haloalkyl, O-C_{1-6} alkyl, O-C_{1-6} haloalkyl, or hydroxy; or

(B) a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein the heteroaromatic ring is:

(i) optionally substituted with from 1 to 4 substituents each of which is independently halogen, -C_{1-6} alkyl, -C_{1-6} haloalkyl, -O-C_{1-6} alkyl, -O-C_{1-6} haloalkyl, or hydroxy; and

(ii) optionally substituted with 1 or 2 substituents each of which is independently aryl or -C_{1-6} alkyl substituted with aryl;

R^2 and R^3 are each independently -H or -C_{1-6} alkyl;

R^4 is:

(1) -H,

(2) -C_{1-6} alkyl,

(3) -C_{1-6} haloalkyl,

(4) -C_{1-6} alkyl substituted with -OH, -O-C_{1-6} alkyl, -O-C_{1-6} haloalkyl, -CN, -$N(R^a)R^b$, -$C(=O)N(R^a)R^b$, -$C(=O)R^a$, -CO_2R^a, -$C(=O)$-$N(R^a)$-C_{1-6} alkylene-OR^b with the proviso that the -$N(R^a)$- moiety and the -OR^b moiety are not both attached to the same carbon of the -C_{1-6} alkylene- moiety, -$S(O)_nR^a$, -$SO_2N(R^a)R^b$, -$N(R^a)C(=O)$-R^b, -$N(R^a)CO_2R^b$, -$N(R^a)SO_2R^b$, -$N(R^a)SO_2N(R^a)R^b$, -$N(R^a)C(=O)N(R^a)R^b$, or -$OC(=O)N(R^a)R^b$,

(5) -$C(=O)R^a$,

(6) -CO_2R^a,

(7) -$C(=O)N(R^a)R^b$,

(8) -$C(=O)$-$N(R^a)$-C_{1-6} alkylene-OR^b with the proviso that the -$N(R^a)$- moiety and the -OR^b moiety are not both attached to the same carbon of the -C_{1-6} alkylene- moiety,

(9) -$N(R^a)$-$C(=O)$-R^b,

(10) -$N(R^a)$-$C(=O)$-$C(=O)N(R^a)R^b$,

(11) -$N(R^a)SO_2R^b$,

(12) -$N(R^a)SO_2N(R^a)R^b$,

(13) -$N(R^a)C(=O)N(R^a)R^b$,

(14) -$OC(=O)N(R^a)R^b$,

(15) -R^K,

(16) $-C(=O)-R^K$,

(17) $-C(=O)N(R^a)-R^K$,

(18) $-C(=O)N(R^a)-C_{1-6}$ alkylene-R^K,

(19) $-C_{1-6}$ alkyl substituted with $-R^K$,

(20) $-C_{1-6}$ alkyl substituted with $-C(=O)-R^K$,

(21) $-C_{1-6}$ alkyl substituted with $-C(=O)N(R^a)-R^K$, or

(22) $-C_{1-6}$ alkyl substituted with $-C(=O)N(R^a)-C_{1-6}$ alkylene-R^K;

wherein R^K is

(i) C_{3-8} cycloalkyl which is optionally substituted with from 1 to 4 substituents each of which is independently halogen, -OH, $-C_{1-6}$ alkyl, $-C_{1-6}$ haloalkyl, $-O-C_{1-6}$ alkyl, or $-O-C_{1-6}$ haloalkyl,

(ii) aryl, which is optionally substituted with from 1 to 5 substituents each of which is independently $-C_{1-6}$ alkyl, $-C_{1-6}$ alkylene-OH, $-C_{1-6}$ alkylene-$O-C_{1-6}$ alkyl, $-C_{1-6}$ alkylene-$O-C_{1-6}$ haloalkyl, $-C_{1-6}$ alkylene-$N(R^a)R^b$, $-C_{1-6}$ alkylene-$C(=O)N(R^a)R^b$, $-C_{1-6}$ alkylene-$C(=O)R^a$, $-C_{1-6}$ alkylene-CO_2R^a, $-C_{1-6}$ alkylene-$S(O)_nR^a$, $-O-C_{1-6}$ alkyl, $-C_{1-6}$ haloalkyl, $-O-C_{1-6}$ haloalkyl, -OH, halogen, $-N(R^a)R^b$, $-C(=O)N(R^a)R^b$, $-C(=O)R^a$, $-CO_2R^a$, $-S(O)_nR^a$, or $-SO_2N(R^a)R^b$,

(iii) HetK, which is a 4- to 7-membered saturated heterocyclic ring containing at least one carbon atom and from 1 to 4 heteroatoms independently selected from N, O and S, wherein the heterocyclic ring is:

(a) optionally substituted with from 1 to 6 substituents each of which is independently halogen, $-C_{1-6}$ alkyl, $-C_{1-6}$ haloalkyl, $-O-C_{1-6}$ alkyl, $-O-C_{1-6}$ haloalkyl, or oxo; and

(b) optionally substituted with aryl or HetC;

wherein HetC is a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein the heteroaromatic ring is optionally fused with a benzene ring, and the optionally fused heteroaromatic ring is optionally substituted with from 1 to 4 substituents each of which is independently $-C_{1-6}$ alkyl, $-C_{1-6}$ haloalkyl, $-O-C_{1-6}$ alkyl, $-O-C_{1-6}$ haloalkyl, or hydroxy; or

(iv) -HetL, which is a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein the heteroaromatic ring is optionally substituted with from 1 to 4 substituents

each of which is independently halogen, -C_{1-6} alkyl, -C_{1-6} haloalkyl, -O-C_{1-6} alkyl, -O-C_{1-6} haloalkyl, or hydroxy;

R^5 is:

(1) -H,

(2) -C_{1-6} alkyl,

(3) -C_{3-8} cycloalkyl optionally substituted with from 1 to 4 substituents each of which is independently halogen, -OH, -C_{1-6} alkyl, -C_{1-6} haloalkyl, -O-C_{1-6} alkyl, or -O-C_{1-6} haloalkyl,

(4) -C_{1-6} alkyl substituted with C_{3-8} cycloalkyl, wherein the cycloalkyl is optionally substituted with from 1 to 4 substituents each of which is independently halogen, -OH, -C_{1-6} alkyl, -C_{1-6} haloalkyl, -O-C_{1-6} alkyl, or -O-C_{1-6} haloalkyl,

(5) -C_{1-6} alkyl substituted with aryl, wherein the aryl is optionally substituted with from 1 to 5 substituents each of which is independently -C_{1-6} alkyl, -C_{1-6} alkylene-OH, -C_{1-6} alkylene-O-C_{1-6} alkyl, -C_{1-6} alkylene-O-C_{1-6} haloalkyl, -C_{1-6} alkylene-$N(R^a)R^b$, -C_{1-6} alkylene-$C(=O)N(R^a)R^b$, -C_{1-6} alkylene-$C(=O)R^a$, -C_{1-6} alkylene-CO_2R^a, -C_{1-6} alkylene-$S(O)_nR^a$, -O-C_{1-6} alkyl, -C_{1-6} haloalkyl, -O-C_{1-6} haloalkyl, -OH, halogen, -$N(R^a)R^b$, -$C(=O)N(R^a)R^b$, -$C(=O)R^a$, -CO_2R^a, -$S(O)_nR^a$, or -$SO_2N(R^a)R^b$, or

(6) -C_{1-6} alkyl substituted with HetD, wherein HetD is:

(i) a 4- to 7-membered saturated heterocyclic ring containing at least one carbon atom and from 1 to 4 heteroatoms independently selected from N, O and S, wherein the heterocyclic ring is optionally substituted with from 1 to 5 substituents each of which is independently halogen, -C_{1-6} alkyl, -C_{1-6} haloalkyl, -O-C_{1-6} alkyl, -O-C_{1-6} haloalkyl, or oxo; or

(ii) a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein the heteroaromatic ring is optionally substituted with from 1 to 4 substituents each of which is independently -C_{1-6} alkyl, -C_{1-6} haloalkyl, -O-C_{1-6} alkyl, -O-C_{1-6} haloalkyl, or hydroxy;

each aryl is independently phenyl, naphthyl, or indenyl;

each R^a is independently H or C_{1-6} alkyl;

each R^b is independently H or C_{1-6} alkyl; and

each n is independently an integer equal to zero, 1, or 2.

21. (previously presented) A compound according to claim 20, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:

methyl 6-(4-fluorobenzyl)-4-hydroxy-3, 5-dioxo-2,3,5,6,7,8-hexahydro-2,6-naphthyridine-1-carboxylate;

6-(4-fluorobenzyl)-4-hydroxy-*N*,*N*-dimethyl-3,5-dioxo-2,3,5,6,7,8-hexahydro-2,6-naphthyridine-1-carboxamide;

N-cyclobutyl-6-(4-fluorobenzyl)-4-hydroxy-3,5-dioxo-2,3,5,6,7,8-hexahydro-2,6-naphthyridine-1-carboxamide;

N-cyclopropyl-6-(4-fluorobenzyl)-4-hydroxy-3,5-dioxo-2,3,5,6,7,8-hexahydro-2,6-naphthyridine-1-carboxamide;

6-(4-fluorobenzyl)-4-hydroxy-*N*-isopropyl-3,5-dioxo-2,3,5,6,7,8-hexahydro-2,6-naphthyridine-1-carboxamide;

6-(4-fluorobenzyl)-4-hydroxy-N-methyl-3,5-dioxo-2,3,5,6,7,8-hexahydro-2,6-naphthyridine-1-carboxamide;

6-(4-fluorobenzyl)-4-hydroxy-3, 5-dioxo-2,3,5,6,7,8-hexahydro-2,6-naphthyridine-1-carboxylic acid;

N-[6-(4-fluorobenzyl)-3,4-dihydroxy-5-oxo-5,6,7,8-tetrahydro-2,6-naphthyridin-1-yl]-N-methylmethanesulfonamide;

N-[6-(4-fluorobenzyl)-4-hydroxy-2-methyl-3,5-dioxo-2,3,5,6,7,8-hexahydro-2,6-naphthyridin-1-yl]-N-methylacetamide;

6-(4-fluorobenzyl)-4-hydroxy-*N*, *N*, 2-trimethyl-3,5-dioxo-2,3,5,6,7,8-hexahydro-2,6-naphthyridine-1-carboxamide;

6-(3-chloro-4-fluorobenzyl)-4-hydroxy-N,N,2-trimethyl-3,5-dioxo-2,3,5,6,7,8-hexahydro-2,6-naphthyridine-1-carboxamide; and

6-(4-fluorobenzyl)-4-hydroxy-N,N,2-trimethyl-3,5-dioxo-2,3,5,6-tetrahydro-2,6-naphthyridine-1-carboxamide.